Clarivate Epidemiology's coverage of ACS comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of acute coronary syndrome for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology's ACS forecast will answer the following questions:
How will improvements in survival change the number of people living with a diagnosis of acute coronary syndrome?
Of all people diagnosed with ACS, how many in each country across the world are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ACS over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient flow diagrams are provided at the regional level, but they may be requested for any specific country or forecast year.
In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least ten years of forecast data for the following acute coronary syndrome subpopulations:
Diagnosed events – NSTEMI by drug-treatment status.
Diagnosed events – STEMI by drug-treatment status.
Alison Isherwood, M.Sc., M.Res., Ph.D., is a senior director on the Epidemiology team at Clarivate. She specializes in female cancers, biomarker, and infectious disease epidemiology, particularly involving the impact of vaccination. She holds a B.Sc. in medical microbiology, a master’s degree in research in the life sciences (specializing in virology and parasitology), and an M.Sc. in epidemiology, all from the University of Edinburgh. She also holds a Ph.D. in molecular virology from the University of Reading in England.
